<DOC>
	<DOCNO>NCT00287261</DOCNO>
	<brief_summary>In trial , question address zoledronic acid ( Zometa , Novartis Pharma ) could clinical benefit patient myelofibrosis myeloid metaplasia ( MMM ) .</brief_summary>
	<brief_title>A Trial Zoledronic Acid Patients With Myelofibrosis With Myeloid Metaplasia ( MMM )</brief_title>
	<detailed_description>This prospective , multicentre phase II study adult patient document MMM require therapy disease . Patients treat every 3 week 4 mg zoledronic acid ( Zometa ) , administer 15 min . intravenous infusion . Study duration 36 week ( 12 infusion ) . After study recommend continue treatment disease progression , occurrence unacceptable treatment-related toxicity . Objectives trial : Primary objective : effect monthly infusion zoledronic acid 4 mg : hemoglobin level , spleen size Secondary objective effect monthly infusion zoledronic acid 4 mg : red blood cell transfusion need performance status constitutional symptom leukocyte count thrombocyte count bone marrow fibrosis serum LDH</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>male female least 18 yearsofage histologically confirm diagnosis myelofibrosis myeloid metaplasia ( MMM ) . This include patient agnogenic myeloid metaplasia ( also know idiopathic myelofibrosis ) patient precede history polycythemia vera essential thrombocytemia ( also know postpolycytemic myelofibrosis ) . ( see Appendix A ) patient low , intermediate high risk disease category ( follow Dupriez score ) may include presence measurable , clinically relevant disease manifestation ( especially low risk patient ) ECOG performance status 0 , 1 2 life expectancy least 3 month Women childbearing potential must use medically acceptable form contraception study must negative urine serum pregnancy test within 7 day randomization write informed consent disease associate secondary myelofibrosis , metastatic carcinoma , lymphoma , myelodysplasia , hairy cell leukemia , mast cell disease , acute leukemia ( include M7 disease acute panmyelosis myelofibrosis ) presence chromosomal translocation ( 9:22 ) molecular BCR/ABL rearrangement detect RTPCR bone marrow peripheral blood antimyelofibrosis drug therapy last 4 week . This include chemotherapy , androgen , steroid , thalidomide , hematopoietic growth factor investigational drug patient receive bisphosphonates previous 3 month know allergy intolerance bisphosphonates abnormal renal function evidence : calculate creatinine clearance &lt; 30 ml/min ( creatinine clearance ( CrCl ) calculate use Cockcroft Gault formula ) ( see Appendix F ) correct serum calcium &lt; 8.0 mg/dL . Corrected serum calcium ( mg/dl ) = measure calcium ( mg/dl ) + 0.8* [ 4 patient serum albumin ( g/dl ) ] patient nonmalignant condition would confound evaluation primary endpoint , impair tolerance therapy , prevent compliance protocol , include : uncontrolled infection uncontrolled type 2 Diabetes Mellitus diseases influence bone metabolism Paget 's disease uncontrolled thyroid parathyroid dysfunction cardiovascular , renal , hepatic , pulmonary neurologic/psychiatric disease would prevent prolonged followup current active dental problem include infection teeth jawbone ( maxilla mandibula ) ; dental fixture trauma , current prior diagnosis osteonecrosis jaw , expose bone mouth , slow healing dental procedure recent ( within 6 week ) plan dental jaw surgery ( e.g . extraction , implant ) patient history noncompliance medical regimen patient consider potentially unreliable and/or cooperative patient treat systemic investigational drug within past 4 week topical investigational drug within past 7 day pregnant breast feeding female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>myelofibrosis</keyword>
	<keyword>D009191</keyword>
</DOC>